New Stem Cell-Based Application for BeyondSpring’s Plinabulin Presented at ISSCR Annual Meeting
June 30, 2020
Data Presented Shows Plinabulin Mobilizes Bone Marrow CD34+ Progenitor Cells through a Mechanism of Action Independent from G-CSFs and CXCR4
NEW YORK, June 30, 2020 (GLOBE NEWSWIRE) — BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that the Company presented clinical data on BeyondSpring’s first-in-class, late-stage asset, Plinabulin, showing potent CD34+ progenitor cell mobilization from bone marrow, which has broad applications for stem cell-based therapies, gene therapy and regenerative medicine. These findings potentially add another indication to Plinabulin, which is known as a “pipeline in a drug.” Dr. Ramon Mohanlal, BeyondSpring’s Chief Medical Officer and Executive Vice President, Research and Development, presented this new data as a poster at this year’s ISSCR Annual Meeting.
Current approved agents for CD34+ progenitor cell mobilization, such as G-CSFs or Plerixafor (CXCR4-antagonist), have many limitations. While G-CSFs are highly effective in preventing chemotherapy-induced neutropenia (CIN), they come with severe side effects, such as bone pain and thrombocytopenia. To add, multiple doses of short-acting G-CSFs (up to six or seven) are often needed for the therapy to be effective. Plerixafor is also given by daily injections for four to five days and is a very expensive process and not as effective for CD34+ cells (American Health and Drug Benefits, 2012).
Additionally, G-CSFs are contra-indicated in Sickle Cell Disorder (SCD) patients undergoing gene therapy. This results in high rates of adverse events requiring hospitalization, including vaso-occlusive crises, multi-organ failure and even death (Chien, Haematologica 2018). Lastly, when side effects such as bone pain, leukocytosis (high white blood cell count) and / or myalgia (muscle pain) occur, a G-CSF dose is often reduced to 50 percent, which is less effective for CD34+ cell mobilization.
Plinabulin is a novel and potent agent for the prevention of CIN and does not cause bone pain or thrombocytopenia. Plinabulin is given as a single fixed dose (40mg) – as a 30-minute intravenous infusion – and has a mechanism of action independent from G-CSF of CXCR4.
In BeyondSpring’s PROTECTIVE-2 Phase 2 study, the team evaluated the effects of CD34+ cell mobilization through combining Plinabulin with the full dose of Pegfilgrastim (Peg) at 6mg and at lower doses of 3mg and 1.5mg in breast cancer patients receiving taxotere, doxorubicin and cyclophosphamide (TAC).
The data shows that combining Plinabulin with a low dose of Pegfilgrastim produces statistically significant CD34+ cell counts (p<0.03) and increases to values that are comparable to, or numerically higher than, the full dose of Pegfilgrastim alone under severe myelosuppressive conditions.
In BeyondSpring’s PROTECTIVE-1 Phase 2 study, the Company previously reported that lung cancer patients receiving docetaxel who received a single dose of Plinabulin saw an increase of CD34+ counts to clinically and statistically significant (p<0.001) levels under myelosuppressive conditions (Blayney, ASH 2018).
The above data presentation is available on the “Posters” page of BeyondSpring’s website. Please click here for more information.
“Plinabulin’s mechanism of action for CD34+ cell mobilization, which is independent from G-CSFs or CXCR4, offers an important alternative to patients who do not adequately respond to these agents, including patients where G-CSFs are contra-indicated,” said Dr. Mohanlal. “Stem cell-based applications, such as gene therapy, is bound to become the standard of care for SCD, for which Plinabulin is well-positioned for CD34+ cell mobilization, given that G-CSFs are contra-indicated for SCD patients. With more than 100,000 SCD patients in the U.S. alone, this represents a near-term opportunity for Plinabulin, along with other CD34+ progenitor cell applications.”
Headquartered in New York, BeyondSpring is a global, clinical-stage biopharmaceutical company focused on developing innovative immuno-oncology cancer therapies to improve clinical outcomes for patients with high unmet medical needs. BeyondSpring’s first-in-class lead immune asset, Plinabulin, is a potent antigen-presenting cell (APC) inducer. It is currently in two Phase 3 clinical trials for two severely unmet medical needs indications: one is for the prevention of chemotherapy-induced neutropenia (CIN), the most frequent cause for a chemotherapy regimen dose’s decrease, delay, downgrade or discontinuation, which can lead to suboptimal clinical outcomes. The other is for non-small cell lung cancer (NSCLC) treatment in EGFR wild-type patients. As a “pipeline drug,” Plinabulin is in various I/O combination studies to boost PD-1 / PD-L1 antibody anti-cancer effects. In addition to Plinabulin, BeyondSpring’s extensive pipeline includes three pre-clinical immuno-oncology assets and a drug discovery platform dubbed “molecular glue” that uses the protein degradation pathway.
Plinabulin, BeyondSpring’s lead asset, is a differentiated immune and stem cell modulator. Plinabulin is currently in late-stage clinical development to increase overall survival in cancer patients, as well as to alleviate chemotherapy-induced neutropenia (CIN). The durable anticancer benefits of Plinabulin have been associated with its effect as a potent antigen-presenting cell (APC) inducer (through dendritic cell maturation) and T-cell activation (Chem and Cell Reports, 2019). Plinabulin’s CIN data highlights the ability to boost the number of hematopoietic stem / progenitor cells (HSPCs), or lineage-/cKit+/Sca1+ (LSK) cells in mice. Effects on HSPCs could explain the ability of Plinabulin to not only treat CIN but also to reduce chemotherapy-induced thrombocytopenia and increase circulating CD34+ cells in patients.
Cautionary Note Regarding Forward-Looking Statements
This press release includes forward-looking statements that are not historical facts. Words such as “will,” “expect,” “anticipate,” “plan,” “believe,” “design,” “may,” “future,” “estimate,” “predict,” “objective,” “goal,” or variations thereof and variations of such words and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are based on BeyondSpring’s current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors including, but not limited to, difficulties raising the anticipated amount needed to finance the Company’s future operations on terms acceptable to the Company, if at all, unexpected results of clinical trials, delays or denial in regulatory approval process, results that do not meet our expectations regarding the potential safety, the ultimate efficacy or clinical utility of our product candidates, increased competition in the market, and other risks described in BeyondSpring’s most recent Form 20-F on file with the U.S. Securities and Exchange Commission. All forward-looking statements made herein speak only as of the date of this release and BeyondSpring undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.
RECENT NEWS ARTICLES
BeyondSpring Strengthens Board with the Addition of Ex-Immunomedics and Constellation Commercial Head Brendan Delaney
NEW YORK, July 14, 2021 -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global pharmaceutical company focused on the development of cancer therapeutics, today announced the appointment of Brendan Delaney to its Board of Directors, effective...
NEW YORK, July 08, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (“BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that management will participate in the William Blair Biotech...
BeyondSpring to Host R&D Day to Discuss Novel Immune Agent Plinabulin’s Development Program in Anti-cancer Indications
NEW YORK, June 17, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced it will host a Research and Development...
- NDA Filed by U.S. Food and Drug Administration (FDA) and given Priority Review for plinabulin plus G-CSF for the prevention of CIN. A PDUFA date of November 30, 2021 has been assigned by the FDA - Highlighted PROTECTIVE-2 Phase 3 data at two scientific conferences –...
BeyondSpring to Host First Quarter Financial Results and Corporate Update Conference Call on June 16, 2021
NEW YORK, June 11, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (“BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that management will host a conference call to report its...
BeyondSpring Announces Final Positive Data from the PROTECTIVE-1 Phase 3 CIN Program of Plinabulin as a Single Agent Compared to Pegfilgrastim at the American Society of Clinical Oncology (ASCO) Annual Meeting
- Data further supports plinabulin’s fast onset of action and CIN prevention benefit in week 1 following chemotherapy - Single agent plinabulin (day 1 dose as chemotherapy), had non-inferior protection against CIN compared to pegfilgrastim (day 2 dose), while...
BeyondSpring Announces a Late-Breaking Poster Presentation of PROTECTIVE-2 Phase 3 Data Showing Plinabulin, in Combination with Pegfilgrastim, Reverses the Immune-Suppressive Effects of Pegfilgrastim and Offers Superior Prevention of Chemotherapy-Induced Neutropenia (CIN) at the FOCIS Annual Meeting
Presentation data demonstrates that plinabulin, in combination with pegfilgrastim, not only improves CIN prevention but also reverses some of the immune suppressive profile of monotherapy pegfilgrastim NEW YORK, June 08, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the...
BeyondSpring Announces Three Presentations Highlighting Positive Clinical Outcome Data from the Phase 3 Program of Plinabulin in Combination with Pegfilgrastim for the Prevention of Chemotherapy-Induced Neutropenia at the American Society of Clinical Oncology (ASCO) Annual Meeting
- Data demonstrate that combination of plinabulin and pegfilgrastim offers superior benefit for reducing the incidence and severity of febrile neutropenia (FN) and hospitalization, with better quality-of-life (QoL), compared to pegfilgrastim alone NEW YORK, June 07,...
BeyondSpring Announces First Patient Dosed in a Triple Combination Study with Plinabulin, PD-1/PD-L1 Inhibitor and Radiotherapy for the Reversal of Resistance to PD-1/PD-L1 Inhibitors in Patients with Advanced Solid Tumors
Resistance to immunotherapy is a severe unmet medical need that plinabulin aims to address in combination with checkpoint inhibitors and radiotherapy First patient who failed Keytruda and chemotherapy has been dosed with plinabulin, Keytruda and radiation combination...
BeyondSpring Announces U.S. FDA Acceptance and Priority Review of New Drug Application for Plinabulin and G-CSF Combination for the Prevention of Chemotherapy-Induced Neutropenia (CIN)
- The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date for November 30, 2021 - Plinabulin and G-CSF combination has the potential to raise the standard of care in CIN prevention for the first time in 30 years NEW YORK, June 01, 2021 (GLOBE...
RECENT MEDIA COVERAGE
Seed Therapeutics Launches Protein Degradation Research Platform and Appoints Edward Dongheng Liu as Chief Financial Officer
JAMA Oncology Highlights Plinabulin’s Efficacy in Preventing Chemotherapy-Induced Neutropenia as a Monotherapy